{"entity":{"id":"nct06155084","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","aka":[],"tldr":"A phase 1/2 trial of HP518 - Dose Escalation in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.","summary":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients is a phase 1/2 interventional study registered as NCT06155084 by Hinova Pharmaceuticals Inc., with 84 participants planned, started 2023-12-26 and due to reach its primary completion in 2026-03. Interventions recorded: HP518 - Dose Escalation and HP518 -Dose Expansion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06155084","url":"https://clinicaltrials.gov/study/NCT06155084"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06155084","phase":"1/2","setting":"A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China","sponsor":"Hinova Pharmaceuticals Inc.","enrolled":84,"outcomes":[]},"route":"/trials/nct06155084/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}]}}